CD5 and CD43 expression are associate with poor prognosis in DLBCL patients
Huang Hui,
Li Zhandong,
Huang Chuansheng,
Rao Jun,
Xie Qin,
Cui Wenhao,
Tou Fangfang,
Zheng Zhi
Affiliations
Huang Hui
Department of Integration of Chinese and Western Medicine, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital & Institute, Beijing, Beijing 100142, P. R China
Li Zhandong
Department of Integration of Chinese and Western Medicine, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital & Institute, Beijing, Beijing 100142, P. R China
Huang Chuansheng
Department of Internal Medicine 5th Division Jiangxi Cancer Center, Jiangxi Cancer Hospital, Nanchang University, Nanchang, 330029P.R. China
Rao Jun
Department of Internal Medicine 5th Division Jiangxi Cancer Center, Jiangxi Cancer Hospital, Nanchang University, Nanchang, 330029P.R. China
Xie Qin
Department of Internal Medicine 5th Division Jiangxi Cancer Center, Jiangxi Cancer Hospital, Nanchang University, Nanchang, 330029P.R. China
Cui Wenhao
Department of Pharmacology, Kyoto Prefectural University of Medicine, Kyoto, 602-8566, Japan
Tou Fangfang
Department of Internal Medicine 5th Division Jiangxi Cancer Center, Jiangxi Cancer Hospital, Nanchang University, Nanchang, 330029P.R. China
Zheng Zhi
Department of Internal Medicine 5th Division Jiangxi Cancer Center, Jiangxi Cancer Hospital, Nanchang University, Nanchang, 330029P.R. China
